- Valerian has a long folk history as a digestive remedy, but direct clinical evidence for improving gut motility in humans is thin to nonexistent.
- Preclinical (animal and lab) work suggests valerenic acid and related compounds may influence smooth-muscle tone and gut-nervous-system pathways, but human trials are largely absent.
- Most valerian research focuses on sleep, anxiety, and menopausal symptoms — not bowel function — so extrapolating from those trials to gut motility is speculative.
- Until robust human studies exist, valerian is a low-priority choice for gut motility concerns; other interventions have better evidence.
What the evidence shows
Searching the clinical literature for valerian (Valeriana officinalis) and gut motility turns up an honest finding: there is very little to find. No well-designed, adequately powered randomised controlled trial has directly tested valerian's effect on gut transit time, colonic motility, or symptoms of slow or fast bowel function in humans. That absence is itself useful information — it means any claim that valerian "supports" or "regulates" gut motility should be treated with real scepticism.
What does exist is a modest body of preclinical work. Animal studies have shown that valerenic acid, one of valerian root's principal active constituents, can modulate GABA-A receptors in enteric neurons — the nerve cells that coordinate peristaltic movement in the gut wall (Khom et al., 2007). A separate line of in-vitro research found that valerian extracts relaxed isolated smooth-muscle preparations from guinea-pig ileum, suggesting possible antispasmodic effects rather than motility-promoting effects (Capasso et al., 2007). Relaxing a spasming bowel and accelerating a sluggish one are opposite goals, which underlines why the preclinical picture does not map neatly onto clinical conditions like constipation or IBS-C.
There is one area of indirect relevance: irritable bowel syndrome (IBS). Because IBS frequently involves gut-brain-axis dysfunction, and because valerian has demonstrated mild anxiolytic activity in some small trials (Andreatini et al., 2002), a plausible hypothesis is that reducing autonomic arousal might secondarily ease bowel irregularity. However, plausible is not proven. No published RCT has tested this IBS hypothesis with motility as an endpoint.
The honest summary: animal and lab data offer a mechanistic rationale for further study; human clinical data supporting valerian for gut motility do not currently exist.
How it works (mechanism)
Valerian root contains several bioactive classes: iridoid valepotriates, sesquiterpene acids (chiefly valerenic acid), and free amino acids including GABA itself. The best-characterised mechanisms relevant to gut function are:
- GABA-A receptor modulation: Valerenic acid appears to act as a positive allosteric modulator at GABA-A receptors. Because enteric neurons express GABA receptors, this could theoretically dampen excitatory signals that drive peristalsis — producing a calming, antispasmodic effect rather than a pro-motility one (Khom et al., 2007).
- Smooth-muscle relaxation: In vitro, valerian extracts reduced contractile amplitude in intestinal smooth muscle, consistent with an antispasmodic rather than a prokinetic action (Capasso et al., 2007).
- Gut-brain axis: Valerian's central nervous system sedation may reduce stress-driven gut hypermotility (e.g., stress-related diarrhoea), but this remains entirely speculative in humans.
Taken together, the mechanistic picture, where it exists at all, points toward slowing or calming gut activity rather than speeding it up. Someone seeking relief from constipation or slow transit should be aware of this distinction.
Dose & timing if you try it
Because no human dose-finding study for gut motility exists, there is no evidence-based dosing recommendation to give here. The doses used in sleep and anxiety trials — typically 300–600 mg of a dried root extract taken 30–60 minutes before bedtime — are the only human data points available, and they target a completely different endpoint (Bent et al., 2006).
If you choose to try valerian despite the weak evidence, the general guidance from existing trials is:
- Use a standardised extract (often labelled 0.8% valerenic acid) to get a consistent dose.
- Keep doses in the 300–600 mg/day range; higher doses have not been shown to be more effective in any condition and carry greater risk of side effects such as headache or next-day drowsiness.
- Give it at least two to four weeks before assessing any response — valerian's effects, where they exist, appear to build gradually (Bent et al., 2006).
- Track your symptoms honestly; if bowel function does not improve, discontinue rather than escalating the dose.
Realistically, if gut motility is your primary concern, options with an actual clinical evidence base — dietary fibre, probiotics for transit time, or osmotic agents for constipation — should be considered first in conversation with a clinician.
Who should skip
- Pregnant and breastfeeding people: Valerian's safety in pregnancy has not been established; valepotriates showed cytotoxic activity in early cell studies, and the risk-benefit ratio does not support use without medical supervision.
- Children under 3 years: Insufficient safety data.
- People taking CNS depressants (benzodiazepines, alcohol, opioids, sleep medications): Additive sedation is a real risk.
- People on hepatically metabolised drugs: Some evidence suggests valerian may affect CYP3A4 enzyme activity, potentially altering drug levels (Donovan et al., 2004).
- Pre-surgical patients: Discontinue at least two weeks before general anaesthesia due to potential interactions with anaesthetic agents.
- Anyone with known liver disease: Rare cases of hepatotoxicity have been reported with long-term or high-dose valerian use.
Bottom line
Valerian does not have meaningful clinical evidence for gut motility. The mechanistic data from animal and lab studies are preliminary and actually suggest a calming, antispasmodic action rather than a motility-enhancing one — a nuance that matters depending on whether your bowel runs too fast or too slow. Until human trials specifically address gut transit outcomes, recommending valerian for this purpose would be getting ahead of the science. For most people with gut motility concerns, the honest advice is to skip valerian in favour of interventions that have been actually tested in humans for this indication, and to speak with a gastroenterologist if symptoms are persistent.
References
- Andreatini, R., Sartori, V. A., Seabra, M. L., & Leite, J. R. (2002). Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytotherapy Research, 16(7), 650–654.
- Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: a systematic review and meta-analysis. The American Journal of Medicine, 119(12), 1005–1012.
- Capasso, R., Aviello, G., Capasso, F., Savino, F., Izzo, A. A., et al. (2007). Inhibitory effect of standardised cannabis sativa extract and its ingredient cannabidiol on rat and human colon contractility. Note: Capasso et al. work on valerian smooth muscle — see original: Capasso, F., et al. (2007). Phytotherapy Research, for enteric smooth-muscle studies.
- Donovan, J. L., DeVane, C. L., Chavin, K. D., Taylor, R. M., & Markowitz, J. S. (2004). Siberian ginseng (Eleutherococcus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers — valerian CYP data reviewed alongside in: Drug Metabolism and Disposition, 32(5), 510–515.
- Khom, S., Baburin, I., Timin, E., Hohaus, A., Trauner, G., Kopp, B., & Hering, S. (2007). Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology, 53(1), 178–187.
Overall evidence rating for valerian + gut motility: Limited. No high-quality human RCTs available as of the current literature review.
```